Media headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.1298644994913 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) – Here’s What to Focus on – Nasdaq Journal (press release) (nasdaqjournal.com)
- Aurinia Pharmaceuticals (AUPH) Upgraded to Sell by BidaskClub (americanbankingnews.com)
- Here’s What Knocked Aurinia Pharmaceuticals Inc. Down 16.1% in December (fool.com)
- Aurinia Pharmaceuticals Files New Preliminary Base Shelf … – Markets Insider (markets.businessinsider.com)
- Aurinia Pharmaceuticals Inc (AUPH) Shares Dip on New Shelf Registration – Smarter Analyst (smarteranalyst.com)
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.21 on Monday. The company has a market cap of $437.50, a PE ratio of -4.31 and a beta of 2.34. Aurinia Pharmaceuticals has a twelve month low of $2.12 and a twelve month high of $10.54.
A number of brokerages have recently commented on AUPH. Leerink Swann lifted their price objective on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 15th. ValuEngine raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Canaccord Genuity set a $11.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 17th. Finally, Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $10.79.
WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/08/aurinia-pharmaceuticals-auph-getting-somewhat-positive-news-coverage-study-finds.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.